Literature DB >> 10889534

mu-opioid receptor and alpha2-adrenoceptor agonist stimulation of [35S]GTPgammaS binding to G-proteins in postmortem brains of opioid addicts.

J J Meana1, J González-Maeso, J A García-Sevilla, J Guimón.   

Abstract

Repeated opioid administration has been associated in human brain with unaltered density of mu-opioid receptors (agonist radioligand binding sites and immunodetected receptor protein). These receptors are coupled to Gi/Go-proteins, which are increased in brain of heroin addicts. To assess the activity of G-proteins and their coupling to receptors after chronic opioid abuse, [35S]GTPgammaS binding was quantified in postmortem prefrontal cortices of 15 opioid-dependent subjects and 15 matched controls. The stimulation of [35S]GTPgammaS binding by the mu-opioid receptor agonist DAMGO or the alpha2-adrenoceptor agonist UK14304 was used as a functional measure of the status of the receptor-G-protein coupling. [35S]GTPgammaS binding basal values were similar in opioid addicts (819+/-83 fmol mg-1 of protein) and controls (918+/-106 fmol mg(-1) of protein). In opioid addicts, [35S]GTPgammaS binding stimulation by DAMGO showed a maximal effect (62+/-8%) and a potency (EC50 = 1.09+/-0.26 microM) that did not differ from the maximal effect (60+/-12%) and potency (EC50 = 2.01+/-0.58 microM) in controls. In opioid addicts, [35S]GTPgammaS binding stimulation by UK14304 was not different in maximal effect (28+/-3%) from controls (32+/-8%), but the potency of the agonist was decreased (EC50 = 4.36+/-1.81 microM) when compared with controls (EC50 = 0.41+/-0.15 microM). The results provide a direct evidence of an apparent normal functional activity of brain mu-opioid receptors (Gi/Go-protein coupling) during the opioid dependence process in humans. The data also demonstrate a functional uncoupling of alpha2-adrenoceptors from G-proteins, which indicates a heterologous desensitization of these receptors. This finding could represent an adaptive mechanism against the decreased noradrenergic activity induced by the chronic presence of opioid drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10889534     DOI: 10.1038/sj.mp.4000727

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  5 in total

Review 1.  Heteromerization of G protein-coupled receptors: relevance to neurological disorders and neurotherapeutics.

Authors:  Laura Albizu; José L Moreno; Javier González-Maeso; Stuart C Sealfon
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

2.  Increased functional coupling of the mu opioid receptor in the anterior insula of depressed individuals.

Authors:  Pierre-Eric Lutz; Daniel Almeida; Dominique Filliol; Fabrice Jollant; Brigitte L Kieffer; Gustavo Turecki
Journal:  Neuropsychopharmacology       Date:  2021-02-02       Impact factor: 7.853

Review 3.  GPCR oligomers in pharmacology and signaling.

Authors:  Javier González-Maeso
Journal:  Mol Brain       Date:  2011-05-27       Impact factor: 4.041

4.  Adrenergic Agonists Bind to Adrenergic-Receptor-Like Regions of the Mu Opioid Receptor, Enhancing Morphine and Methionine-Enkephalin Binding: A New Approach to "Biased Opioids"?

Authors:  Robert Root-Bernstein; Miah Turke; Udaya K Tiruttani Subhramanyam; Beth Churchill; Joerg Labahn
Journal:  Int J Mol Sci       Date:  2018-01-17       Impact factor: 5.923

5.  Characterization of dopamine D2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia.

Authors:  Iker Egusquiza; Eva Munarriz-Cuezva; Rafael Segarra; Javier González-Maeso; Luis F Callado; J Javier Meana; Rebeca Diez-Alarcia
Journal:  Pharmacol Rep       Date:  2021-07-01       Impact factor: 3.024

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.